Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
Pharmacology, Toxicology and Pharmaceutical Science
4
7%
Biochemistry, Genetics and Molecular Biology
3
5%
Agricultural and Biological Sciences
3
5%
Nursing and Health Professions
2
3%
Other
1
2%
Unknown
26
45%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 August 2023.
All research outputs
#7,944,015
of 27,057,185 outputs
Outputs from Head & Neck
#675
of 4,401 outputs
Outputs of similar age
#104,361
of 330,013 outputs
Outputs of similar age from Head & Neck
#9
of 48 outputs
Altmetric has tracked 27,057,185 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 4,401 research outputs from this source. They receive a mean Attention Score of 2.7. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,013 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.
